| The process of differentiating the Linde Gas Therapeutics business began in the mid-nineties. Since that time the company has been systematically growing its competence in the area of therapeutics and its development of inhaled nitric oxide (NO) as a pharmaceutical, through all its phases, has given a head start.
Today, Linde Gas Therapeutics consists of two business divisions: Hospital Care and Respiratory Homecare. The Hospital Care division supplies pharmaceutical and medical device gases to more than 600 clinics and hospitals. The Respiratory Homecare division is a service business that provides ventilation and oxygen therapy to home patients suffering from cardio-pulmonary diseases, chronic obstructive pulmonary disease (COPD) and sleep disorders.
The role of the INO Therapeutics division is to build a world-class critical care pharmaceutical franchise for INOmax® inhaled nitric oxide, a unique proprietary therapy for neonatal intensive care units. It is the fist gas that was successfully developed as a drug used in medical therapies. It is also a model for future gas enabled treatment. INOmax received FDA approval for the treatment of hypoxic respiratory failure in certain newborns in December 1999 and European marketing authorization in August 2001.
Related links:
www.linde-gastherapeutics.com
www.inotherapeutics.com |
